Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiation and Surgery in Stage III NSCLC
NCT03871153Phase 2Terminated
- Start
- Aug 2019
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC). Primary endpoint: Pathologic Complete Response Rate at 3 months. Started Aug 2019; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03871153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871153.